Elagolix Curbs Heavy Bleeding Linked to Uterine Leiomyomas Elagolix Curbs Heavy Bleeding Linked to Uterine Leiomyomas

Elagolix sodium, an oral short-acting nonpeptide gonadotropin-releasing hormone antagonist has been approved by the FDA at a dose of 300 mg twice daily with add-back therapy for up to 24 months.MDedge News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Source Type: news